Challenges of Iranian Clinicians in Dealing with COVID-19: Taking Advantages of The Experiences in Wenzhou.
Anti-inflammatory Drug
Antiviral Drug
COVID-19
Diagnosis
SARS-CoV-2
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
05
05
2020
accepted:
12
06
2020
entrez:
12
8
2020
pubmed:
12
8
2020
medline:
12
8
2020
Statut:
ppublish
Résumé
The novel coronavirus has been spreading since December 2019. It was initially reported in Wuhan, Hubei province of China. Coronavirus disease 2019 (COVID-19) has currently become a pandemic affecting over seven million people worldwide, and the number is still rising. Wenzhou, as the first hit city out of Hubei Province, achieved a remarkable success in effectively containing the disease. A great record was also observed in Wenzhou for the clinical management of COVID-19 patients, leading to one of the lowest death rates in China. Researchers and clinical specialists proposed and formulated combined approaches such as computerized tomography (CT)- scans and molecular assays, as well as using both allopathic and traditional medications to mitigate its effects. Iranian and Chinese specialists and scientists had a communication in clinical, molecular and pharmaceutical aspects of COVID-19. A proper guideline was prepared according to the experiences of Chinese clinicians in managing the full spectrum of COVID-19 patients, from relatively mild to highly complex cases. The purpose of this guideline is to serve a reference in the hospital for specialists so that they may better diagnose cases and provide effective therapies and proposed antiviral and anti-inflammatory drugs for patients.
Identifiants
pubmed: 32779447
doi: 10.22074/cellj.2020.7604
pmc: PMC7481903
doi:
Types de publication
Journal Article
Langues
eng
Pagination
155-165Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
JAMA. 2020 Feb 25;323(8):709-710
pubmed: 31999307
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2020 Jun 9;323(22):2338-2340
pubmed: 32412606
Front Med. 2020 Apr;14(2):220-224
pubmed: 32166600
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Int J Infect Dis. 2020 May;94:78-80
pubmed: 32251794
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
Clin Infect Dis. 2020 May 01;:
pubmed: 32357206
Front Med (Lausanne). 2020 Apr 24;7:170
pubmed: 32391369
J Mol Med (Berl). 2020 Jun;98(6):789-803
pubmed: 32494931
J Virol. 2020 Jun 16;94(13):
pubmed: 32303592
Crit Care. 2020 Apr 16;24(1):154
pubmed: 32299472
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Tidsskr Nor Laegeforen. 2020 Apr 11;140(7):
pubmed: 32378842
Stem Cells Int. 2019 Feb 4;2019:4130757
pubmed: 30863450
Med Hypotheses. 2020 May 30;143:109862
pubmed: 32504923
Engineering (Beijing). 2020 Mar 18;:
pubmed: 32346491
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1021-1026
pubmed: 32285293
Eur Respir J. 2020 May 14;55(5):
pubmed: 32299867
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264